CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has presented long-term treatment and survival data for sugemalimab at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting. The data comes from the GEMSTONE-302 study, which combines sugemalimab with platinum-based chemotherapy.
The Phase III trial, a multicenter, randomized, double-blind study, evaluates the efficacy and safety of sugemalimab combined with platinum-based chemotherapy as a first-line treatment for patients with Stage IV non-small cell lung cancer (NSCLC), compared to a placebo combined with chemotherapy. As of the data cutoff on May 15, 2023, the median overall survival (OS) in the sugemalimab group was 25.2 months compared to 16.9 months in the placebo group (HR=0.68 [95% CI, 0.54-0.85]), with four-year OS rates of 32.1% and 17.3%, respectively. Among the 58 patients who received sugemalimab for over two years, the median duration of response (DoR) was not reached, and the four-year OS rate was 92.6%. In patients with baseline brain metastases, the combination of sugemalimab and platinum-based chemotherapy continued to extend both progression-free survival (PFS) and OS compared to placebo and chemotherapy, with a median OS of 26 months versus 9.0 months. The safety profile of sugemalimab in combination with chemotherapy was consistent with previously reported results. -Fineline Info & Tech
